Loading
A phase 2 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC is a phase 2 interventional study registered as NCT06745323 by Amgen, with 252 participants enrolled, started 2025-02-26 and due to reach its primary completion in 2029-05-10. Interventions recorded: Tarlatamab. Conditions listed: Small Cell Lung Cancer (SCLC). No results are recorded here; the registry entry is the source.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).